论文部分内容阅读
目的:研究双路途径腹腔化疗加静脉化疗治疗晚期卵巢恶性肿瘤疗效。方法:52例晚期卵巢恶性肿瘤患者,腹腔加静脉化学治疗,腹腔化疗采取单针腹腔穿刺,腹腔用药:顺铂(DDP)80mg/m2~100mg/m2,足叶乙苷(VP16)200mg/m2,静脉用药:环磷酰胺(CTX)600mg/m2~800mg/m2,每3周1周期,化疗4周期~6周期。结果:总有效率86.53%,1a、2a、3a、4a、5a生存率分别为86.53%、73.07%、65.38%、57.69%、44.23%,最长1例生存期已达10a以上,无严重毒副反应发生。结论:双路途径腹腔化疗加静脉化疗治疗晚期卵巢恶性肿瘤,有效率较高,毒副作用较轻,可望使晚期卵巢恶性肿瘤患者的化疗适应范围增加,使更多患者能提高生存质量,延长生存期。
Objective: To study the efficacy of dual-path intraperitoneal chemotherapy plus intravenous chemotherapy in the treatment of advanced ovarian cancer. Methods: Fifty-two patients with advanced ovarian cancer were treated with intraperitoneal chemotherapy and intraperitoneal chemotherapy. Single-needle peritoneal puncture was performed in peritoneal cavity. DDP 80mg / m2 ~ 100mg / m2, VP16 200mg / m2 , Intravenous drug: cyclophosphamide (CTX) 600mg / m2 ~ 800mg / m2, every 3 weeks 1 cycle, chemotherapy 4 cycles to 6 cycles. Results: The total effective rate was 86.53%. The survival rates of 1a, 2a, 3a, 4a and 5a were 86.53%, 73.07%, 65.38%, 57.69% and 44.23% Side effects occur. Conclusion: The dual-path chemotherapy plus intravenous chemotherapy in the treatment of advanced ovarian cancer with high efficiency and less toxic side effects is expected to increase the scope of chemotherapy in patients with advanced ovarian cancer, so that more patients can improve the quality of life and prolong Survival.